MétaCan
Menu
Back to cohort
Record W4318542651 · doi:10.1111/add.16147

Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials

2023· review· en· W4318542651 on OpenAlexafffundabout
Daniela K van Santen, Sara Lodi, Paul Dietze, Wijnand van den Boom, Kanna Hayashi, Huiru Dong, Zishan Cui, Lisa Maher, Matthew Hickman, Anders Boyd, Maria Prins

Bibliographic record

VenueAddiction · 2023
Typereview
Languageen
FieldMedicine
TopicHIV, Drug Use, Sexual Risk
Canadian institutionsInstitute of Infection and ImmunityBritish Columbia Centre on Substance UseSimon Fraser University
FundersNational Institute on Drug AbuseRijksinstituut voor Volksgezondheid en MilieuNational Institute of Allergy and Infectious DiseasesMedical Research CouncilStichting Sanquin BloedvoorzieningNational Institutes of HealthMichael Smith Health Research BCUniversiteit van AmsterdamCenter for AIDS Research, University of WashingtonStichting HIV MonitoringAmsterdam University Medical CentersNational Institute for Health and Care ResearchNational Institute for Health Research Health Protection Research UnitSt. Paul's FoundationBurnet Institute
KeywordsMedicineCohortSyringeHepatitis CHarm reductionCohort studyInternal medicineDrug injectionHepatitis C virusHazard ratioDrugHuman immunodeficiency virus (HIV)PharmacologyVirologyConfidence intervalVirusPsychiatry

Abstract

fetched live from OpenAlex

Abstract Background and Aims Although the Netherlands, Canada and Australia were early adopters of harm reduction for people who inject drugs (PWID), their respective HIV and hepatitis C (HCV) epidemics differ. We measured the pooled effect of needle and syringe program (NSP) and opioid agonist therapy (OAT) participation on HIV and HCV incidence in these settings. Design For each cohort, we emulated the design and statistical analysis of a target trial using observational data. Setting and Participants We included PWID at risk of HIV or HCV infection from the Amsterdam Cohort Studies (1985–2013), Vancouver Injection Drug Users Study (1997–2009) and Melbourne Injecting Drug User Cohort Study (SuperMIX) (2010–2021). Measurements Separately for each infection and cohort (only HCV in SuperMIX), marginal structural models were used to compare the effect of comprehensive (on OAT and 100% NSP coverage or on OAT only if no recent injection drug use) versus no/partial NSP/OAT (no OAT and/or <100% NSP coverage) participation. Pooled hazard ratios (HR) and 95% CI were calculated using random‐effects meta‐analysis. Findings We observed 94 HIV seroconversions and 81 HCV seroconversions among 2023 and 430 participants, respectively. Comprehensive NSP/OAT led to a 41% lower risk of HIV acquisition (pooled HR = 0.59, 95% CI = 0.36–0.96) and a 76% lower risk of HCV acquisition (pooled HR = 0.24, 95% CI = 0.11–0.51), compared with no/partial NSP/OAT, with little heterogeneity between studies for both infections ( I 2 = 0%). Conclusions In the Netherlands, Canada and Australia, comprehensive needle and syringe program and opioid agonist therapy participation appears to substantially reduce HIV and hepatitis C acquisition compared with no or partial needle and syringe program/opioid agonist therapy participation. These findings from an emulated trial design reinforce the critical role of comprehensive access to harm reduction in optimizing infection prevention for people who inject drugs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.965
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.060
GPT teacher head0.381
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations20
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueAddictionSame topicHIV, Drug Use, Sexual RiskFrench-language works237,207